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Purpose: To characterize the effects of circadian rhythm, feeding time, age, general anesthesia, and ocular hypotensive
compounds on intraocular pressure (IOP) of the Tibetan monkey (Macaca thibetana).
Methods: Tibetan monkeys were trained for IOP measurement with the TonoVet® rebound tonometer without sedation
or anesthesia. Their circadian IOP fluctuation was monitored every 3 h. Effects of changing the feeding time, general
anesthesia, age (2–3 year-old versus 8–15 year-old animals), and various pharmacological agents, such as travoprost,
timolol, naphazoline and spiradoline, on IOP were also evaluated.
Results: After behavioral training, conscious Tibetan monkeys were receptive to IOP measurement. The lowest and
highest IOP values in a circadian cycle were recorded at 3:00 AM (19.8±0.4 mmHg, mean±SEM, n=12) and noon
(29.3±0.9 mmHg), respectively. Changing the feeding time from 11:30 AM to 12:30 PM lowered the noon IOP to
25.1±1.2 mmHg. General anesthesia lowered IOP in these monkeys, while IOP of young and mature animals were similar.
Three hours after topical ocular administration, travoprost reduced IOP by 5.2±0.6 mmHg (n=6, p<0.001), and timolol
reduced IOP by 2.8±0.7 mmHg (p<0.05). Naphazoline and spiradoline lowered IOP by 4.8 mmHg and 2.5 mmHg (both
p<0.001), respectively, 2 h after drug administration.
Conclusions: The circadian IOP fluctuation in conscious Tibetan monkeys and their responses to travoprost, timolol, and
other experimental conditions are similar to other primates. These monkeys appear to be a suitable model for glaucoma
research.
Glaucoma is one of the leading causes of irreversible
vision loss worldwide, estimated to affect 80 million by 2020
[1]. This disease is a complex, age-related, and inherited optic
neuropathy with characteristic slow progressive loss of retinal
ganglion cells and excavation of the optic disc. An elevated
intraocular  pressure  (IOP)  is  a  major  risk  factor.  Many
prospective and randomized clinical trials have consistently
demonstrated that lowering IOP is important in slowing the
progression of glaucoma, as well as preventing and delaying
its  onset  [2-6].  Correspondingly,  all  currently  available
glaucoma treatments, be they pharmaceutical or surgical, are
designed to lower IOP [7].
Animal models are widely used and critical in glaucoma
research, especially for the evaluation and development of
IOP-lowering  therapies.  Various  laboratories  have  used
rodent,  rabbit,  feline,  canine,  porcine,  bovine,  and  ovine
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models  for  this  purpose  [8].  Recently,  mouse  models  of
glaucoma have become popular. Aided by the power of mouse
genetics,  they  allow  researchers  to  dissect  pathogenic
pathways responsible for glaucomatous damage to the eye at
the  molecular  and  genetic  levels  [9-11].  Despite  the
advantages  of  the  various  animal  models,  non-human
primates are very valuable because of their anatomic and
functional similarities to human in ocular structures relevant
to  the  disease  [12,13].  All  approved  IOP-lowering
medications lower IOP in the monkey [14]. Development of
novel IOP-lowering therapies also often depends on critical
in vivo findings provided by the monkey model. Hence, they
are  highly  valuable  for  glaucoma  research.  The  most
commonly  used  monkeys  for  IOP  studies  have  been  the
cynomolgus monkeys and rhesus monkeys [15-17].
To expand the repertoire of monkey models for glaucoma
research, in the current report, we describe previously un-
characterized IOP responses of the Tibetan monkey (Macaca
thibetana)  under  baseline  and  various  experimental
conditions.  The  Tibetan  monkey,  also  known  as  Chinese
Stump-tailed  Macaque  or  Milne-Edwards'  Macaque,  is  a
widely  distributed  non-human  primate  in  central  and
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1405southwestern  China,  ranging  as  far  south  as  the  Guangxi
province and as far west as the Yangtze Gorges in western and
northwestern  Sichuan  province.  These  animals  live  in
broadleaf evergreen, subtropical, and deciduous forests 1 to
2.5  km  in  elevation.  They  are  predominantly  diurnal  and
frugivorous,  but  also  consume  other  parts  of  plants  and
invertebrates.  Compared  to  rhesus  monkeys  (Macaca
mulatta), Tibetan monkeys have larger body size, longer life
span (over 20 years), calmer temperament, and are easier to
train [18]. They are legally approved to be used for scientific
research by the State Forestry Administration in the People’s
Republic of China.
In this study, we have trained Tibetan monkeys to calmly
allow IOP measurement by the TonoVet® rebound tonometer
without sedation or anesthesia. The circadian fluctuation of
IOP and influences of general anesthesia, age, and feeding
time on IOP were evaluated. Additionally, the IOP effects of
clinical IOP-lowering medications, such as travoprost and
timolol,  as  well  as  experimental  compounds,  such  as
adrenergic and imidazoline receptor agonist naphazoline and
kappa  opioid  agonist  spiradoline,  which  were  reported  to
lower  rabbit  IOP  [19,20],  were  also  assessed  in  these
monkeys.  To  our  knowledge,  this  is  the  first  report
characterizing  the  IOP  responses  of  conscious  Macaca
thibetana.  These  observations  may  serve  as  an  initial
foundation for the use of these animals as a model for studying
glaucoma and IOP-lowering therapies.
METHODS
Animals: Twelve young (2–3 years old) and six mature (8–15
years old) Tibetan monkeys in equal numbers of males and
females were used in this study. They were purpose-bred for
research use by the Institute of Laboratory Animal Sciences,
Sichuan Academy of Medical Sciences (Chengdu, China). All
animal experiments were conducted in compliance with the
ARVO Statement for the Use of Animals in Ophthalmic and
Vision Research, the Guide for the Care and Use of Laboratory
Animals (National Research Council, Chengdu Sichuan), and
under the supervision of the Institutional Animal Care and Use
Committee in Sichuan University. The animals were housed
under 12-h/12-h light/dark cycle with lights on starting at 6:00
AM  Physical  examinations  including  ophthalmic
examinations  were  conducted  in  all  monkeys  before  the
experiments to exclude potential health factors that might
affect IOP measurements.
Behavioral training: For this study, only the young (2–3 years
old) monkeys were trained for conscious IOP measurement.
The mature (8–15 years old) animals were not trained and used
only for the anesthesia effect study. Behavioral training was
conducted  based  on  the  principle  of  award-conditioned
behavior. Newborn monkeys were raised in the laboratory,
with daily close and friendly interactions with caretakers and
trainers. Training for IOP measurement started at the age of
two. Two trainers participated in the training, one holding the
monkey  gently  in  his  arms,  and  the  other  one  using  the
tonometer to measure IOP. The animal was gently restrained
but not stressed (Figure 1). If the monkey cooperated, a peanut
was given as a reward, which was one of the monkey’s favorite
foods but not provided in its daily food ration. After a five- to
six-month daily training period, all monkeys showed good
tolerance to the tonometer and appeared calm and comfortable
during IOP measurement. Consistent and reproducible IOP
values were easily obtained from these animals.
IOP measurement: IOP was measured using the TonoVet®
rebound tonometer (Tiolat Oy, Helsinki, Finland) according
to the manufacturer’s recommended procedures. We have
Figure 1. Measurement of IOP by the
TonoVet®  rebound  tonometer  in
conscious  Tibetan  monkey.  A  trained
monkey was gently held in an assistant's
arms, allowing IOP measurement with
the rebound tonometer.
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1406previously shown that the equipment reports actual monkey
IOP accurately and reproducibly [13]. The tonometer was
programmed to calculate and display the mean IOP value of
six consecutive, acceptable measurements. In this study, six
mean values were obtained from each eye, at each time point,
under each condition, and the mean of means treated as a
single datum. All IOP measurements were conducted in the
same room at room temperature, with humidity approximately
70%. Illumination intensity was set at 200 lx during the day
(6 AM to 6 PM) and 10 lx at night (6 PM to 6 AM).
Circadian IOP fluctuation study: The 24-h IOP fluctuation
measurements  were  conducted  in  two  studies,  one
predominantly diurnal and the other predominantly nocturnal.
In the diurnal study, IOP was measured every 3 h, at 9:00 AM,
noon, 3:00 PM, 6:00 PM (immediately before lights off), and
9:00  PM  in  the  same  day.  In  the  nocturnal  study,  IOP
measurement was performed 3 days later, at 9:00 PM, mid-
night, 3:00 AM, 6:00 AM (immediately before lights on), and
9:00 AM
Effect of feeding time on IOP: The monkeys were routinely
fed at 11:30 AM To evaluate the effect of this feeding time on
the IOP measurement at noon, feeding time was changed to
12:30 PM for a week, and IOP was measured at noon before
and one week after the change.
Effect of anesthesia and age on IOP of monkeys: Six mature
(8–15  years  old)  monkeys  and  6  young  (2–3  years  old)
monkeys, half males and half females, were used in this study.
At  noon  and  at  3:00  AM,  animals  were  anesthetized  by
ketamine  (50  mg/kg,  intramuscular  injection).  IOP  was
assessed  approximately  5  min  after  the  monkeys  were
injected, at which time they were sufficiently anesthetized to
allow measurement.
Drug  effects  on  IOP:  Effects  of  four  compounds  were
evaluated  in  four  separate  studies.  In  each  study,  trained
animals were randomized and divided into two groups. One
group was treated with topical ocular administration (30 μL)
of BSS® solution (Alcon Laboratories, Fort Worth, TX) as
vehicle control. The other group was treated with one of the
following:  travoprost  (0.004%,  Travatan®;  Alcon
Laboratories),  timolol  (0.5%;  Qingshan  Pharmaceuticals
Company,  Chengdu,  China),  naphazoline  (0.33%  in  0.9%
saline; Sigma, St. Louis, MO), or spiradoline (0.33% in 0.9%
saline; Sigma). IOP measurements by a researcher masked to
the  treatments  were  performed  at  9  AM  (travoprost  and
timolol) or 10 AM (naphazoline and spiradoline) immediately
before drug dosing (time=0 h) and subsequent time points as
indicated. A wash-out period of at least one week between
drug treatments was strictly observed.
Statistics:  Data  were  analyzed  by  SPSS  17.0  statistics
software  (SPSS  Inc.,  Chicago,  IL).  One-way  ANOVA
followed by Bonferroni’s test was used to compare IOP values
among  three  or  more  groups.  IOP  values  between  two
conditions were compared by Two-tailed paired Student’s t-
test. Data are presented as mean ± standard error of mean
(SEM). Differences are regarded as significant when p<0.05.
RESULTS
Circadian IOP fluctuation: Circadian IOP fluctuation was
clearly detected in the conscious Tibetan monkeys. In this
study, measurements of IOP were conducted at 9 AM, noon,
Figure 2. Circadian IOP fluctuation of
conscious Tibetan monkeys. IOP was
measured  by  the  TonoVet®  rebound
tonometer at the indicated times of the
day. Data of two studies conducted three
days  apart  on  the  same  animals  are
presented  together:  the  first  study
monitored IOP from 9 AM to 9 PM; the
second, from 9 PM to 9 AM Symbols
represent mean±SEM (n=12; both eyes
of 6 animals).
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14073 PM, 6 PM (immediately before lights off), and 9 PM in the
same day. Three days later, IOP of the same animals were
monitored  again  at  9  PM,  midnight,  3  AM,  6  AM
(immediately before lights on), and 9 AM By combining data
from these two studies, a 24-h IOP profile was obtained. As
seen in Figure 2, the IOP values of Tibetan monkeys were
generally higher during the day and lower at night. They were
between 20 and 24 mmHg at most time points. However, a
distinct  elevation  of  IOP  was  observed  at  noon
(29.3±0.9  mmHg,  mean±SEM,  n=12).  The  lowest  IOP
reading (19.6±0.8 mmHg) occurred at 3:00 AM (Figure 2).
Effect of feeding time on IOP: The monkeys were routinely
fed at 11:30 AM We speculated that this may contribute to the
elevated IOP observed at noon. To assess this hypothesis, the
feeding time was changed from 11:30 AM to 12:30 PM for
one week, and IOP at noon was measured, before and then one
week after the feeding time change. Changing the feeding time
did affect IOP. When fed at 11:30 AM, monkeys had IOP of
29.2±2.5 mmHg (n=12) at noon. Feeding at 12:30 PM lowered
the noon IOP to 25.1±1.2 mmHg (Figure 3). To be compliant
with the animal care policy of the institute, for all other studies
in this report, animals were fed at 11:30 AM The feeding in
the afternoon was conducted at 4:30 PM, which did not seem
to have the ocular hypertensive effect on the 6:00 PM IOP
measurement.
Effects of anesthesia and age on IOP: Both anesthesia and age
are known to affect IOP. We monitored IOP at noon and 3
AM in six young (2–3 years old) and six mature (8–15 years
old) Tibetan monkeys after general anesthesia by ketamine.
The values were also compared to those of young conscious
monkeys at the same time points. Table 1 shows that at noon,
young  conscious  monkeys  had  the  highest  IOP
(29.3±0.9 mmHg), which was significantly higher than both
anesthetized  young  (22.1±0.7  mmHg)  and  anesthetized
mature  monkeys  (19.9±1.1  mmHg).  Furthermore,  the
anesthetized young monkeys appeared to have a higher IOP
than the anesthetized mature animals, but the difference was
not statistically significant. At 3 AM, IOP was similar among
the three study groups.
Drug effects on IOP of conscious monkeys: To determine the
Tibetan monkey’s IOP responses to pharmacologically active
compounds, travoprost (0.004%; 30 µl) and timolol (0.5%;
30 µl), both of which are widely used ocular hypotensive
drugs approved for human use, were tested in these animals.
Topical ocular administration of either travoprost or timolol
reduced  IOP  in  conscious  Tibetan  monkeys.  After  drug
Figure 3. Effect of feeding time on IOP.
IOP  of  conscious  monkeys  was
measured  at  noon  at  two  different
feeding times: 11:30AM and 12:30 PM
Error bars represent SEM of IOP values
(n=12;  both  eyes  of  6  animals).
***p<0.001  by  paired  two-tailed
Student's t-test.
TABLE 1. EFFECTS OF ANESTHESIA AND AGE ON MONKEY IOP.
Age State n IOP at Noon (mmHg) IOP at 3 AM (mmHg)
Young Conscious 12 29.3±0.9* 19.6±0.8
Young Anesthetized 12 22.1±0.7 19.7±0.4
Matured Anesthetized 12 19.9±1.1 18.0±1.4
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1408treatment,  travoprost  reduced  IOP  by  17.2%  (5.2  mmHg;
p<0.001) from the vehicle group at 3 h, by 20.4% (5.0 mmHg;
p<0.001) at 6 h, and by 20.0% (4.6 mmHg; p<0.001) at 24 h.
No statistical difference was found between thses two group
at 48 h, indicating that the IOP lowering effects of travaprost
lasting less than 48 h (Figure 4). Timolol was also effective
in  lowering  IOP  in  these  monkeys,  though  much  less
efficacious and shorter acting than travoprost. Compared to
the  vehicle-treated  group,  timolol  reduced  IOP  by  8.7%
(2.8 mmHg; p<0.05) at 3 h after drug administration. At 6 h
and 24 h, no significant IOP effect was observed (Figure 5).
Recently,  compounds  that  increase  aqueous
concentrations of natriuretic peptides, such as naphazoline, an
adrenergic  α2  and  imidazoline  I1  receptor  agonist,  and
spiradoline, a kappa opioid receptor agonist, were shown to
Figure 4. Effect of travoprost (0.004%, 30 μl) on IOP of conscious
Tibetan monkeys. The drug was administered topically at 9 AM
(Time 0) onto a randomly assigned eye of each animal, while the
contralateral eye received vehicle as control. IOP was monitored at
3, 6, 24, and 48 h later. Error bars represent SEM (n=6). Top Panel:
IOP values of both groups. ***p<0.001 between the two treatment
groups by two-tailed paired Student's t-test. Bottom panel: % IOP
change of the travoprost group relative to the vehicle control group.
reduce IOP in the rabbit [19,20]. We also evaluated them in
the Tibetan monkeys. Both compounds significantly lowered
monkey  IOP,  although  naphazoline  was  clearly  more
efficacious.  Topical  ocular  administration  of  naphazoline
(100 μg; 0.33%, 30 µl) reduced monkey IOP maximally by
17.4% (4.8 mmHg; p<0.001) at 2 h after treatment. When
compared to the contralateral vehicle-treated eye, a statistical
significant IOP lowering lasted for at least 5 h (Figure 6).
Spiradoline (100 µg; 0.33%, 30 µl) induced a maximum IOP
reduction  of  8.7%  (2.5  mmHg;  p<0.001)  2  h  after  drug
administration (Figure 7).
DISCUSSION
In this study, we successfully trained young Tibetan monkeys
to  accept  IOP  measurement  by  the  handheld  TonoVet®
Figure 5. Effect of timolol (0.5%, 30 μl) on IOP of conscious Tibetan
monkeys. The drug was administered topically at 9 AM (Time 0)
onto a randomly assigned eye of each animal, while the contralateral
eye received vehicle as control. IOP was monitored at 3, 6, and 24 h
later. Error bars represent SEM (n=6). Top Panel: IOP values of both
groups. *p<0.05 between the two treatment groups by two-tailed
paired Student's t-test. Bottom panel: % IOP change of the timolol
group relative to the vehicle control group.
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1409rebound tonometer without sedation or anesthesia. According
to our experience, the Tibetan monkeys, likely because of their
tranquil and calm nature, are much easier to handle than rhesus
and cynomolgus monkeys. Together with the extremely light
touch of the rebound tonometer, it was possible to train them
to allow IOP measurement under gentle restrain in a conscious
state, seemingly without stress or discomfort. As indicated by
the data reported here, the IOP values thus acquired have been
consistent and reproducible.
In the trained young monkeys, we characterized their
circadian IOP fluctuation and found that IOP was between 20
and 24 mmHg at most time points, but was typically higher
during the diurnal phase and lower in the nocturnal phase. This
circadian pattern of IOP changes does not correlate with that
observed in human by Liu et al. [21,22] In the human studies,
Figure 6. Effect of naphazoline (0.3%, 30 µl) on IOP of conscious
Tibetan monkeys. The drug was administered topically at 10 AM
(Time 0) onto a randomly assigned eye of each animal, while the
contralateral eye received vehicle as control Error bars represent
SEM  (n=6).  Top  Panel:  IOP  values  of  both  groups.  *p<0.05,
***p<0.001 between the two treatment groups by two-tailed paired
Student's t-test. Bottom panel: % IOP change of the naphazoline
group relative to the vehicle control group.
the nocturnal IOP was the highest. However, nocturnal IOP
measurements in the human studies were performed with the
subjects in a supine position, while the diurnal measurements
were  conducted  with  the  subjects  sitting.  The  change  in
postures confounds the results. Since the Tibetan monkeys
usually  sleep  in  a  sitting/upright  posture,  and  during  IOP
measurements in this study, they were held in an upright
position, the issue related to supine IOP value does not apply
and may explain the difference in results between this study
and the human IOP studies. Regardless, our findings agree
with previous reports of other monkeys [17]. Both young
rhesus monkeys and cynomolgus monkeys were shown to
have higher IOP in the morning and early afternoon [15,16,
23]. Unique to our findings, we noticed a distinct peak of IOP
Figure 7. Effect of spiradoline (0.3%, 30 µl) on IOP of conscious
Tibetan monkeys. The drug was administered topically at 10 AM
(Time 0) onto a randomly assigned eye of each animal, while the
contralateral eye received vehicle as control Error bars represent
SEM  (n=6).  Top  Panel:  IOP  values  of  both  groups.  *p<0.05,
***p<0.001 between the two treatment groups by two-tailed paired
Student's t-test. Bottom panel: % IOP change of the spiradoline group
relative to the vehicle control group.
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1410at noon. We speculated that this may be a result of the short
duration (approximately 30 min) between feeding and the
assessment of IOP. Indeed, when the feeding time was moved
from 11:30 AM to 12:30 PM, the peak IOP at noon was
significantly diminished. Effect of eating on IOP has been
reported previously [24]. However, the mechanism of this
effect is currently unknown. It is possible that the animals
were  agitated  during  feeding,  which  stimulated  certain
components of the autonomic nervous system and in turn
elevated IOP [25]. Clarification of this awaits further studies.
It is well known that general anesthesia lowers IOP in
animals,  including  monkeys  [15,23,26-28].  We  confirmed
these observations in the Tibetan monkeys. Interestingly, we
found that the IOP-lowering effect of ketamine was prominent
at the peak IOP measured at noon, but not apparent at the
trough IOP recorded at 3 AM, likely because the IOP was
already  low  at  this  time  point.  We  also  found  that  under
anesthesia,  young  and  mature  monkeys  did  not  differ
significantly in their IOP, although the young monkeys had a
slightly  higher  level.  Regardless,  general  anesthesia
confounds interpretation of the IOP data. Measurement on
conscious animals avoids such undesirable effect and is thus
clearly preferred.
Tibetan monkeys respond to clinically available ocular
hypotensive medications similar to other primates. Travoprost
is an ester prodrug of a potent FP prostaglandin receptor
agonist, widely used as a treatment for glaucoma [29]. FP
prostaglandin agonists, such as travoprost and latanoprost, are
potent and efficacious IOP-lowering drugs in monkeys [29,
30]. These compounds typically cause a reduction of IOP with
a 2 to 4 h lag time after topical administration and the effect
lasted for at least 24 h [16,31,32]. In the current study, we
confirmed the prolonged IOP-lowering effect of travoprost in
the Tibetan monkeys: the drug reduced IOP by approximately
20% for more than 24 h.
The beta-adrenergic receptor antagonist timolol was also
effective in lowering IOP in the Tibetan monkeys. However,
it  was  clearly  less  efficacious  than  travoprost;  an  IOP
reduction of only 2.8 mmHg was seen. This result is similar
to those reported in other monkey species. Although timolol
lowers IOP by more than 9 mmHg in laser photocoagulation-
induced  ocular  hypertensive  monkeys  [33],  it  typically
produces rather small effects in normotensive monkey eyes.
For example, in the normotensive cynomolgus monkey eyes,
timolol only lowers IOP by approximately 2 mmHg [34]. In
normotensive  eyes  of  rhesus  monkey,  only  a  2.6  mmHg
reduction was reported [35]. Hence, regarding beta-blockers,
the IOP response of the Tibetan monkey agrees with other
primates.
In addition to confirming the IOP responses of these
monkeys to known ocular hypotensive agents, we also tested
effects of novel compounds. In the rabbit, naphazoline, an
adrenergic  α2  and  imidazoline  I1  receptor  agonist,  and
spiradoline, a kappa opioid receptor agonist, were shown to
increase natriuretic peptide levels in the aqueous humor [19,
20].  Natriuretic  peptides  in  ocular  tissues  elevate  cellular
levels of cyclic GMP, which has been demonstrated to lower
IOP [36,37]. Indeed, both naphazoline and spiradoline lower
rabbit  IOP  [19,20].  We  confirmed  that  in  the  Tibetan
monkeys,  these  compounds  lower  monkey  IOP,  with
naphazoline  being  more  efficacious.  These  preliminary
findings  support  further  careful  evaluation  of  this
pharmacological  class  of  compounds  for  potential  novel
treatment of glaucoma.
Thus,  we  have  demonstrated  that  after  behavioral
training, IOP measurement can be performed in conscious
Tibetan  monkeys.  Their  baseline  IOP,  circadian
characteristics,  and  responses  to  several  compounds  are
similar to other monkey species. Because of their tame, calm
nature, these monkeys are easy to handle. Their relatively long
life span among macaques allows a long-term, sustainable use
for experiments, which reduces the costs of procurement and
training. These advantages make them a viable alternative
primate model for glaucoma research and evaluation of IOP-
lowering compounds.
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